Obesity is considered a chronic disease that increases the risk of developing diseases that reduce life expectancy. The treatment of obesity is complex. However, treatments based exclusively on dietary changes have not shown long-term efficacy especially in people with severe obesity. In contrast, in this group of people bariatric surgery (BS) has shown good long-term results in weight loss and maintenance. These changes are accompanied by significant improvements in health, improved quality of life, and reduced mortality. However, the changes in the digestive system created by BS and the high level of dietary restriction, affect the nutritional status and require a proper supplementation of vitamins and minerals during the follow-up. Intense weight loss during the first few months, coupled with an insufficient amount of protein in the diet, can lead to a loss of muscle mass. Excessive muscle loss during the short-term period can lead to functional repercussions (decreased strength and physical function) and reduced calories that the body burns daily. Naturally, this is especially important in people suffering from sarcopenia before BS, and it occurs more frequently in postmenopausal women. Despite this is known, specific protein intake recommendations after BS have not yet been defined based on scientific evidence. In this context, the first part of our proposal will assess the effect of two levels of protein supplementation: standard (S-PS) versus high (H-PS) on changes in a) body composition, b) energy expenditure, c) metabolic flexibility d) the physical condition during weight loss that follows BS. In addition, in patients with H-PS, the added effect of a physical exercise program, carried out with a personal trainer (professional of sports medicine trainer) virtually, will be evaluated. Protein supplementation and the virtual exercise program will be done during the 4 months following BS, and the results will be studied at 4, 8, and 12 months. Once the results have been defined, it is essential to transfer the recommendations to the real world. In a second part, and to achieve knowledge transfer to clinical practice, the investigators will explore the key elements that influence patient experience (XPA).
Obesity is considered a chronic disease that increases the risk of developing diseases that reduce life expectancy. The treatment of obesity is complex. However, treatments based exclusively on dietary changes have not shown long-term efficacy especially in people with severe obesity. In contrast, in this group of people bariatric surgery (BS) has shown good long-term results in weight loss and maintenance. These changes are accompanied by significant improvements in health, improved quality of life, and reduced mortality. However, the changes in the digestive system created by BS and the high level of dietary restriction, affect the nutritional status and require a proper supplementation of vitamins and minerals during the follow-up. Intense weight loss during the first few months, coupled with an insufficient amount of protein in the diet, can lead to a loss of muscle mass. Excessive muscle loss during the short-term period can lead to functional repercussions (decreased strength and physical function) and reduced calories that the body burns daily. Naturally, this is especially important in people suffering from sarcopenia before BS, and it occurs more frequently in postmenopausal women. Despite this is known, specific protein intake recommendations after BS have not yet been defined based on scientific evidence. In this context, the first part of our proposal will assess the effect of two levels of protein supplementation: standard (SP-S) versus high (SP-A) on changes in a) body composition, b) energy expenditure, c) metabolic flexibility d) the physical condition during weight loss that follows BS. In addition, in patients with SP-Alta, the added effect of a physical exercise program, carried out with a personal trainer (professional of sports medicine trainer) virtually, will be evaluated. Protein supplementation and the virtual exercise program will be done during the 4 months following CO, and the results will be studied at 4, 8, and 12 months. Once the results have been defined, it is essential to transfer the recommendations to the real world. In a second part, and to achieve knowledge transfer to clinical practice, the investigators will explore the key elements that influence patient experience (XPA). The investigators will define indicators to assess it, especially those that are related to adherence to nutritional recommendations and to changes in lifestyle. The investigators are currently in the recruitment phase of the study. I have studied the necessary elements, ambitions and included the components that will help to define the dietary and lifestyle recommendations for our population. Aim to facilitate and define the performance of the professionals providing realistic, based on the XPA and in this way to improve the impact of the CO on health and quality of life. This is an ambitious and necessary study and includes all the component that will help define dietary and lifestyle recommendations for our population. It aims to facilitate and define the action of professionals provides realistic tools, based on XPA and thus improve the impact of BS on health and quality of life. Description of the population to study sedentary women, candidates for BS at our institution.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
75
protein supplements will be supplied to participants at no cost physical activity Will be performed virtually by PT
Hospital Clinic Barcelona
Barcelona, Spain
effect of PS and PA on Changes in fat mass and Fat free mass (kg)
change from baseline in DEXA values
Time frame: 4 months after BS
effect of PS and PA on Changes in fat mass and Fat free mass (kg)
change from baseline in DEXA values
Time frame: 8 months after BS
effect of PS and PA on Changes in fat mass and Fat free mass (kg)
change from baseline in DEXA values
Time frame: 12 months after BS
effect of PS and PA on resting energy expenditure (REE) (Kcal/ day)
change from baseline in estimated REE from indirect calorimety
Time frame: 4 months after BS
effect of PS and PA on resting energy expenditure (REE) (Kcal/ day)
change from baseline in estimated REE from indirect calorimety
Time frame: 8 months after BS
effect of PS and PA on resting energy expenditure (REE) (Kcal/ day)
change from baseline in estimated REE from indirect calorimety
Time frame: 12 months after BS
Strength
changes from baseline on prediction of ne repetition máximum (1-RM) and hang grip.
Time frame: 4 months after BS
Strength
changes from baseline on prediction of ne repetition máximum (1-RM) and hang grip.
Time frame: 8 months after BS
Strength
changes from baseline on prediction of ne repetition máximum (1-RM) and hang grip.
Time frame: 12 months after BS
Functionality
changes from baseline on sit and stand
Time frame: 4 months after BS
Functionality
changes from baseline on sit and stand
Time frame: 8 months after BS
Functionality
changes from baseline on sit and stand
Time frame: 12 months after BS
Metabolic flexibility - oxidation of substrates: VO2 peak
change in VO2 peak measured by Ergocard during half-effort test
Time frame: 4 months after BS
Metabolic flexibility - oxidation of substrates: VO2 peak
change in VO2 peak measured by Ergocard
Time frame: 8 months after BS
Metabolic flexibility - oxidation of substrates: VO2 peak
change in VO2 peak measured by Ergocard during half-effort test
Time frame: 12 months after BS
Respiratory quotient
change in RQ determined by Ergocard during half-effort test
Time frame: 4 months after BS
Respiratory quotient
change in RQ determined by Ergocard during half-effort test
Time frame: 8 months after BS
Respiratory quotient
change in RQ determined by Ergocard during half-effort test
Time frame: 12 months after BS
Fat oxidation (FatMax) during during half-effort test
Time to spend to reach the cross over pony for RQ=1 determined by Ergocard during half-effort test (min)
Time frame: 4 months after BS
Fat oxidation (FatMax) during during half-effort test
Time to spend to reach the cross over pony for RQ=1 determined by Ergocard during half-effort test (min)
Time frame: 8 months after BS
Fat oxidation (FatMax) during during half-effort test
Time to spend to reach the cross over pony for RQ=1 determined by Ergocard during half-effort test (min)
Time frame: 12 months after BS
Adherence to PS (BCAA biomarker)
serum change in BCAA (mcg)
Time frame: 4 months after BS
Adherence to PS (BCAA biomarker)
serum change in BCAA (mcg)
Time frame: 8 months after BS
Adherence to PS (BCAA biomarker)
serum change in BCAA (mcg)
Time frame: 12 months after BS
Adherence to PS (urinary nitrogen 24hs.)
Nitrogen (mg) values quantified in 24hs urine
Time frame: 4 months after BS
Adherence to PS (urinary nitrogen 24hs.)
Nitrogen (mg) values quantified in 24hs urine
Time frame: 8 months after BS
Adherence to PS (urinary nitrogen 24hs.)
Nitrogen (mg) values quantified in 24hs urine
Time frame: 12 months after BS
Understand patients' priorities and the "painful points" of the care process. Explore the magnitude of these "painful points." This should make it possible to prioritize the areas to be evaluated. Test assessment tools
identify by focus group patient reported outcomes by cualitative study
Time frame: 12 months after BS
Changes in BMI
weight and height will be combined to report BMI in kg/m\^2
Time frame: 4 months after BS
Changes in BMI
weight and height will be combined to report BMI in kg/m\^2
Time frame: 8 months after BS
Changes in BMI
weight and height will be combined to report BMI in kg/m\^2
Time frame: 12 months after BS
Insulin sensitivity (HOMA-IR)
fasting glucose (mg) and insulin (miliunits/ liter) will be combined to report Insulin sensitivity in
Time frame: 4 months after BS
Insulin sensitivity (HOMA-IR)
fasting glucose (mg) and insulin (miliunits/ liter) will be combined to report Insulin sensitivity in
Time frame: 8 months after BS
Insulin sensitivity (HOMA-IR)
fasting glucose (mg) and insulin (miliunits/ liter) will be combined to report Insulin sensitivity in
Time frame: 12 months after BS
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.